Approach

Summary

Licensing status

Publication and contact information

Disease models

Transgenic, humanized mouse model of HCV infection

Partially immunocompromised, humanized mice could be used as a model of HCV infection to help evaluate antiviral drug candidates. Transgenic mice with stable expression of human CD81 and occludin (OCLN) in the liver supported HCV entry, but infection was limited to a single cycle. In these transgenic mice, deletion of signal transducer and activator of transcription 1 (Stat1) rendered the animals partially immunocompromised and susceptible to HCV entry, infection and replication. Next steps include selecting viral variants that replicate more robustly in a series of mouse strains with progressively compromised immune systems to establish a fully competent mouse model of HCV infection.
Apath LLC is in discussion with The Jackson Laboratory to make the mouse model available to the research community.

SciBX 6(34); doi:10.1038/scibx.2013.941
Published online Sept. 5, 2013

Use of OCLN in the mouse model of HCV patented by Apath; available for licensing from Apath
Contact: Robert Roth, Apath LLC, St. Louis, Mo.
e-mail:
aproth@apath.com

Dorner, M. et al. Nature;
published online July 31, 2013;
doi:10.1038/nature12427
Contact: Alexander Ploss,
Princeton University, Princeton, N.J.
e-mail:
aploss@princeton.edu
Contact: Charles M. Rice,
The Rockefeller University, New York, N.Y.
e-mail:
ricec@rockefeller.edu